Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.4%

2 terminated out of 58 trials

Success Rate

91.3%

+4.8% vs benchmark

Late-Stage Pipeline

24%

14 trials in Phase 3/4

Results Transparency

10%

2 of 21 completed with results

Key Signals

2 with results91% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (18)
P 1 (1)
P 2 (6)
P 3 (7)
P 4 (7)

Trial Status

Completed21
Unknown17
Recruiting8
Not Yet Recruiting5
Withdrawn4
Terminated2

Trial Success Rate

91.3%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (58)

Showing 20 of 20 trials
NCT07571460Phase 4Completed

Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis

NCT05782556Recruiting

Freiburg TIPS Registry

NCT07560202Active Not Recruiting

Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors

NCT05625893Phase 2Completed

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

NCT07521332Phase 4Recruiting

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

NCT07461545Not ApplicableRecruiting

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

NCT07461532Not ApplicableRecruiting

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

NCT07473375RecruitingPrimary

Indicators Affecting PVT Recanalization

NCT07422701Not Yet RecruitingPrimary

Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation

NCT05166239Phase 2Completed

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

NCT07252570Completed

Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes

NCT06513780RecruitingPrimary

A Study of the Correlation Between Portal Vein Thrombosis and Prognosis of Liver Transplantation

NCT07132515Phase 4Recruiting

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

NCT07062289Not ApplicableNot Yet RecruitingPrimary

Endoscopic Ultrasound-guided Measurement of Portal Vein Pressure Gradient

NCT05360641CompletedPrimary

Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause.

NCT02733770Not ApplicableWithdrawnPrimary

Chances in Portal System Flow After Two Bariatric Procedures

NCT06818279Phase 2Not Yet RecruitingPrimary

Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis

NCT03009461Phase 2Completed

Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis

NCT06319131Not ApplicableNot Yet RecruitingPrimary

Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT

NCT05123326Recruiting

Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome

Scroll to load more

Research Network

Activity Timeline